GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma
GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma
The purpose of this study is to evaluate safety and pharmacokinetic of GP2013 in Japanese
 patients with CD20 positive low tumor burden indolent B-cell NHL under weekly dosing
 schedule.
Inclusion Criteria:

 -  Patient with CD20 positive low tumor burden indolent B-cell non- Hodgkin's lymphoma.

 -  Patient with at least one measurable lesion.

 -  Patient with ECOG performance status 0 or 1.

 Exclusion Criteria:

 -  Patient who has received radiotherapy within the last 28 days prior to administration,
 or are not recovered from previous radiotherapy.

 -  Patient who has received immunotherapy, chemotherapy, antibodies and experimental
 treatment within the last 28 days prior to administration, or are not recovered from
 previous therapy.

 -  Patient who has mAb therapy other than rituximab as prior line of therapy.

 -  Patient with evidence of any uncontrolled, acute or chronic active infection (viral,
 bacterial or fungal).

 -  Patient with any other malignancy within 5 years prior to date of screening, with the
 exception of adequately treated in situ carcinoma of the cervix uteri, basal or
 squamous cell carcinoma or nonmelanomatous skin cancer.

 Other protocol-defined inclusion/exclusion criteria may apply.